Hospital
Plainview Hospital
Plainview Hospital was paid $6.39M by Medicaid between Jan 2018 and Dec 2024, across 102 billing codes. Its largest line is 99284, emergency room visit (serious) — 22% of everything it billed.
33Billing provider infoPLAINVIEW HOSPITAL
PLAINVIEW, NY 11803
PLAINVIEW, NY 11803
33aNPI1083621130assigned 08/02/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.39M
24GClaims142,630
24DCodes billed102
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#89 of 231
Median peer was paid$561K
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CUSACK, MICHELE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,270 | $45K | |
| 2019 | 7,954 | $410K | |
| 2020 | 19,729 | $1.04M | |
| 2021 | 28,150 | $1.40M | |
| 2022 | 28,232 | $1.19M | |
| 2023 | 32,499 | $1.33M | |
| 2024incomplete | 24,796 | $963K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 7,945 | 7,622 | $1.38M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 5,273 | 5,151 | $1.02M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10.0% | 3,416 | 3,339 | $638K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.8% | 1,729 | 1,711 | $372K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 5.2% | 590 | 588 | $335K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.2% | 1,725 | 1,694 | $331K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.9% | 1,588 | 1,558 | $315K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.6% | 2,072 | 2,015 | $292K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 4.4% | 2,301 | 2,238 | $279K |
| 80053 | Comprehensive metabolic panel | 3.1% | 10,308 | 9,817 | $198K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 909 | 893 | $171K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.8% | 525 | 519 | $113K |
90 more codes
| 99213 | Doctor's office visit, returning patient (routine) | 1.4% | 881 | $90K |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 13,159 | $76K |
| C1889 | Implantable/insertable device, not otherwise classified | 1.0% | 204 | $66K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,746 | $62K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,933 | $54K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 891 | $49K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 290 | $48K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 287 | $40K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 58 | $31K |
| 86850 | <1% | 1,982 | $31K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,946 | $29K |
| 86900 | <1% | 1,990 | $29K | |
| 86901 | <1% | 1,990 | $27K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,601 | $21K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 99 | $18K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 469 | $17K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 26 | $17K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,831 | $17K |
| 84702 | <1% | 3,704 | $15K | |
| 0225U | <1% | 1,101 | $15K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 616 | $15K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,330 | $14K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,236 | $14K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,328 | $13K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 937 | $13K |
| 85027 | <1% | 4,344 | $10K | |
| 83880 | <1% | 448 | $10K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 527 | $10K |
| 87631 | <1% | 194 | $9K | |
| 88312 | <1% | 548 | $8K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 573 | $8K |
| J3490 | Unclassified drugs | <1% | 2,304 | $7K |
| 81025 | <1% | 2,116 | $7K | |
| 88304 | <1% | 184 | $7K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,350 | $6K |
| 82962 | <1% | 1,877 | $6K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 756 | $6K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 29 | $5K |
| 85610 | <1% | 2,293 | $4K | |
| 85730 | <1% | 2,214 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,988 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 327 | $3K |
| 70498 | <1% | 12 | $2K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,303 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 482 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,097 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 691 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,616 | $2K |
| 83690 | <1% | 3,356 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 208 | $1K |
| 81001 | <1% | 2,828 | $1K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 24 | $1K |
| 84484 | <1% | 2,727 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 125 | $920.62 |
| J2704 | Injection, propofol, 10 mg | <1% | 329 | $743.32 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 14 | $707.55 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 49 | $610.04 |
| 85379 | <1% | 1,228 | $587.88 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 31 | $362.72 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 319 | $312.46 |
| 83735 | <1% | 1,003 | $290.83 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 14 | $261.03 |
| 83605 | <1% | 979 | $253.84 | |
| 90715 | <1% | 12 | $243.60 | |
| 87486 | <1% | 34 | $237.51 | |
| 87581 | <1% | 34 | $237.51 | |
| 88313 | <1% | 382 | $216.98 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 17 | $209.64 |
| 81003 | <1% | 856 | $205.80 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 227 | $198.52 |
| 87040 | <1% | 442 | $180.84 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 43 | $180.37 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 225 | $151.31 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 116 | $140.31 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 53 | $117.98 |
| 73630 | <1% | 28 | $73.94 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 145 | $65.39 |
| 82553 | <1% | 150 | $54.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 33 | $52.10 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 39 | $51.35 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 13 | $33.28 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 13 | $21.70 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 17 | $20.94 |
| 82550 | <1% | 110 | $14.63 | |
| 87186 | <1% | 16 | $13.32 | |
| 87081 | 0% | 19 | $0.00 | |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 28 | $0.00 |
| 96376 | 0% | 14 | $0.00 | |
| 70496 | 0% | 12 | $0.00 | |
| 73610 | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCUSACK, MICHELE (SENIOR VICE PRESIDENT & CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.